Ideaya Biosciences Has Dosed Its First Patient In Phase 1 Trial Of IDE397 In Combination With Gilead's Trodelvy (Sacituzumab Govitecan-hziy), In Patients With MTAP-deletion Bladder Cancer
Ideaya Biosciences Has Dosed Its First Patient In Phase 1 Trial Of IDE397 In Combination With Gilead's Trodelvy (Sacituzumab Govitecan-hziy), In Patients With MTAP-deletion Bladder Cancer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.